Please enable JavaScript to continue using this application.

Compare $OKUR vs $RLYB | Chartloom

Compare

$OKUR vs $RLYB

Onkure Therapeutics Inc · Rallybio Corp

OKUR

Onkure Therapeutics Inc

RLYB

Rallybio Corp

Compare $OKUR vs $RLYB

Comparing Onkure Therapeutics Inc and Rallybio Corp

OKUROnkure Therapeutics Inc

RLYBRallybio Corp

OKUROnkure Therapeutics Inc

Market cap

$97M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

71.59x

Rev growth (TTM)

—

YTD performance

-18.6%

52W performance

-20.7%

FCF yield

-49.2%

RLYBRallybio Corp

Market cap

$90M

P/E (TTM)

2.17x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-15.1%

YTD performance

200.8%

52W performance

269.6%

FCF yield

29.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

OKUR

RLYB

Detailed metrics comparison

OKUR

Onkure Therapeutics Inc

RLYB

Rallybio Corp

Market Cap

OKUR$97M

RLYB$90M

Enterprise Value

OKUR$-69M

RLYB$-3M

Price

OKUR$2.41

RLYB$17.02

P/E Ratio

OKURN/A

RLYB2.17x

P/S Ratio

OKUR0.00x

RLYB139.64x

EV/Sales

OKUR0.00x

RLYB-4.09x

EV/EBITDA

OKUR0.00x

RLYB-0.10x

P/B Ratio

OKUR0.60x

RLYB0.96x

P/FCF Ratio

OKURN/A

RLYB3.38x

EV/FCF

OKUR1.44x

RLYB-0.10x

PEG Ratio

OKURN/A

RLYBN/A

Forward P/E (NTM)

OKURN/A

RLYBN/A

Forward P/S (NTM)

OKUR71.59x

RLYBN/A

Revenue (TTM)

OKUR$0

RLYB$646K

Revenue Growth (YoY)

OKURN/A

RLYB-15.1%

Forward Rev Growth

OKUR100.0%

RLYB499.1%

Gross Margin (TTM)

OKUR0.0%

RLYB0.0%

Operating Margin (TTM)

OKUR0.0%

RLYB0.0%

EBITDA Margin (TTM)

OKUR0.0%

RLYB-4284.8%

Net Margin (TTM)

OKUR0.0%

RLYB7051.2%

FCF Margin (TTM)

OKURN/A

RLYB4135.0%

Net Income (TTM)

OKUR$-59M

RLYB$46M

FCF (TTM)

OKUR$-48M

RLYB$27M

EPS (TTM)

OKUR-$1.18

RLYB$7.86

ROE (TTM)

OKUR-4902.0%

RLYB68.6%

ROA (TTM)

OKUR-4577.0%

RLYB64.5%

ROIC (TTM)

OKUR-4902.0%

RLYB68.6%

Cash

OKUR$167M

RLYB$93M

Debt

OKUR$0

RLYB$0

Net Cash/Debt

OKUR$167M

RLYB$93M

Current Ratio (TTM)

OKUR26.75x

RLYB27.26x

Quick Ratio (TTM)

OKUR26.55x

RLYB27.01x

Debt/Equity (TTM)

OKUR0.00x

RLYB0.00x

Debt/Assets (TTM)

OKUR0.0%

RLYB0.0%

Interest Coverage (TTM)

OKURN/A

RLYBN/A

Net Debt/EBITDA (TTM)

OKUR0.00x

RLYB0.00x

Beta

OKUR0.19

RLYB-0.75

52W Performance

OKUR-20.7%

RLYB269.6%

YTD Performance

OKUR-18.6%

RLYB200.8%

% from 52W High

OKUR-55.2%

RLYB-3.2%

% from 52W Low

OKUR13.1%

RLYB363.7%

Asset Turnover (TTM)

OKUR0.00x

RLYB0.01x

FCF Yield (TTM)

OKUR-49.2%

RLYB29.6%

Earnings Yield (TTM)

OKUR-60.3%

RLYB50.5%

Dividend Yield (TTM)

OKURN/A

RLYBN/A

Rule of 40

OKUR0.0

RLYB4,119.9

EV/GP/RG

OKURN/A

RLYBN/A

Ticker research

View OKUR research View RLYB research

Metric	OKUR Onkure Therapeutics Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$97M	$90M
Enterprise Value	$-69M	$-3M
Price	$2.41	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	0.00x	139.64x
EV/Sales	0.00x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	0.60x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	1.44x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	71.59x	N/A
Revenue & Growth
Revenue (TTM)	$0	$646K
Revenue Growth (YoY)	N/A	-15.1%
Forward Rev Growth	100.0%	499.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4284.8%
Net Margin (TTM)	0.0%	7051.2%
FCF Margin (TTM)	N/A	4135.0%
Net Income (TTM)	$-59M	$46M
FCF (TTM)	$-48M	$27M
EPS (TTM)	-$1.18	$7.86
ROE (TTM)	-4902.0%	68.6%
ROA (TTM)	-4577.0%	64.5%
ROIC (TTM)	-4902.0%	68.6%
Financial Health
Cash	$167M	$93M
Debt	$0	$0
Net Cash/Debt	$167M	$93M
Current Ratio (TTM)	26.75x	27.26x
Quick Ratio (TTM)	26.55x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.19	-0.75
52W Performance	-20.7%	269.6%
YTD Performance	-18.6%	200.8%
% from 52W High	-55.2%	-3.2%
% from 52W Low	13.1%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-49.2%	29.6%
Earnings Yield (TTM)	-60.3%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View OKUR research	View RLYB research

Valuation

P/E Ratio

RLYB

2.17x

P/S Ratio

OKUR

0.00x

RLYB

139.64x

EV/FCF

RLYB

-0.10x

OKUR

1.44x

Growth & revenue

Revenue Growth TTM

RLYB

-15.1%

Forward Revenue Growth

RLYB

499.1%

OKUR

100.0%

Profitability & performance

Gross Margin

OKUR

0.0%

RLYB

0.0%

ROE

RLYB

68.6%

OKUR

-4902.0%

FCF Yield %

RLYB

29.6%

OKUR

-49.2%

52-Week Performance

RLYB

269.6%

OKUR

-20.7%

Detailed metrics comparison

OKUR

Onkure Therapeutics Inc

RLYB

Rallybio Corp

Market Cap

OKUR$97M

RLYB$90M

Enterprise Value

OKUR$-69M

RLYB$-3M

Price

OKUR$2.41

RLYB$17.02

P/E Ratio

OKURN/A

RLYB2.17x

P/S Ratio

OKUR0.00x

RLYB139.64x

EV/Sales

OKUR0.00x

RLYB-4.09x

EV/EBITDA

OKUR0.00x

RLYB-0.10x

P/B Ratio

OKUR0.60x

RLYB0.96x

P/FCF Ratio

OKURN/A

RLYB3.38x

EV/FCF

OKUR1.44x

RLYB-0.10x

PEG Ratio

OKURN/A

RLYBN/A

Forward P/E (NTM)

OKURN/A

RLYBN/A

Forward P/S (NTM)

OKUR71.59x

RLYBN/A

Revenue (TTM)

OKUR$0

RLYB$646K

Revenue Growth (YoY)

OKURN/A

RLYB-15.1%

Forward Rev Growth

OKUR100.0%

RLYB499.1%

Gross Margin (TTM)

OKUR0.0%

RLYB0.0%

Operating Margin (TTM)

OKUR0.0%

RLYB0.0%

EBITDA Margin (TTM)

OKUR0.0%

RLYB-4284.8%

Net Margin (TTM)

OKUR0.0%

RLYB7051.2%

FCF Margin (TTM)

OKURN/A

RLYB4135.0%

Net Income (TTM)

OKUR$-59M

RLYB$46M

FCF (TTM)

OKUR$-48M

RLYB$27M

EPS (TTM)

OKUR-$1.18

RLYB$7.86

ROE (TTM)

OKUR-4902.0%

RLYB68.6%

ROA (TTM)

OKUR-4577.0%

RLYB64.5%

ROIC (TTM)

OKUR-4902.0%

RLYB68.6%

Cash

OKUR$167M

RLYB$93M

Debt

OKUR$0

RLYB$0

Net Cash/Debt

OKUR$167M

RLYB$93M

Current Ratio (TTM)

OKUR26.75x

RLYB27.26x

Quick Ratio (TTM)

OKUR26.55x

RLYB27.01x

Debt/Equity (TTM)

OKUR0.00x

RLYB0.00x

Debt/Assets (TTM)

OKUR0.0%

RLYB0.0%

Interest Coverage (TTM)

OKURN/A

RLYBN/A

Net Debt/EBITDA (TTM)

OKUR0.00x

RLYB0.00x

Beta

OKUR0.19

RLYB-0.75

52W Performance

OKUR-20.7%

RLYB269.6%

YTD Performance

OKUR-18.6%

RLYB200.8%

% from 52W High

OKUR-55.2%

RLYB-3.2%

% from 52W Low

OKUR13.1%

RLYB363.7%

Asset Turnover (TTM)

OKUR0.00x

RLYB0.01x

FCF Yield (TTM)

OKUR-49.2%

RLYB29.6%

Earnings Yield (TTM)

OKUR-60.3%

RLYB50.5%

Dividend Yield (TTM)

OKURN/A

RLYBN/A

Rule of 40

OKUR0.0

RLYB4,119.9

EV/GP/RG

OKURN/A

RLYBN/A

Ticker research

View OKUR research View RLYB research

Metric	OKUR Onkure Therapeutics Inc	RLYB Rallybio Corp
Market & Valuation
Market Cap	$97M	$90M
Enterprise Value	$-69M	$-3M
Price	$2.41	$17.02
P/E Ratio	N/A	2.17x
P/S Ratio	0.00x	139.64x
EV/Sales	0.00x	-4.09x
EV/EBITDA	0.00x	-0.10x
P/B Ratio	0.60x	0.96x
P/FCF Ratio	N/A	3.38x
EV/FCF	1.44x	-0.10x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	71.59x	N/A
Revenue & Growth
Revenue (TTM)	$0	$646K
Revenue Growth (YoY)	N/A	-15.1%
Forward Rev Growth	100.0%	499.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-4284.8%
Net Margin (TTM)	0.0%	7051.2%
FCF Margin (TTM)	N/A	4135.0%
Net Income (TTM)	$-59M	$46M
FCF (TTM)	$-48M	$27M
EPS (TTM)	-$1.18	$7.86
ROE (TTM)	-4902.0%	68.6%
ROA (TTM)	-4577.0%	64.5%
ROIC (TTM)	-4902.0%	68.6%
Financial Health
Cash	$167M	$93M
Debt	$0	$0
Net Cash/Debt	$167M	$93M
Current Ratio (TTM)	26.75x	27.26x
Quick Ratio (TTM)	26.55x	27.01x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.19	-0.75
52W Performance	-20.7%	269.6%
YTD Performance	-18.6%	200.8%
% from 52W High	-55.2%	-3.2%
% from 52W Low	13.1%	363.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.01x
FCF Yield (TTM)	-49.2%	29.6%
Earnings Yield (TTM)	-60.3%	50.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	4,119.9
EV/GP/RG	N/A	N/A
Ticker research	View OKUR research	View RLYB research